IBI305
Monoclonal antibody
Evidence outlook
Approved: NSCLC and metastatic colorectal cancer (brand Byvasda) (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
Also approved (1)
- NSCLC and metastatic colorectal cancer (brand Byvasda)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02954172 NCT02954172 · NSCLC This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin. Registry: NCT02954172 | 3 | Objective Response Rate (18 weeks) 2018-10-19 | Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other VEGF-A drugs
Aflibercept, aflibercept-abzv (Enzeevu), aflibercept-ayyh (Pavblu), aflibercept-boav (Eydenzelt), aflibercept-jbvf (Yesafili) and 33 more. Compare all 39 VEGF-A drugs
This mechanism is crowded: 38 other tracked programmes target it, 20 of them ahead of this one.
This drug's own stage for Colorectal Cancer: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| IBI305: this drug | Phase 2 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eylea) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Abzv (Enzeevu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Boav (Eydenzelt) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Brolucizumab-Dbll | Approved(overall) | Antibody fragment | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Encorafenib | Approved | Small molecule | BRAF V600E | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Approved | Small molecule | VEGFR1/2/3 | Reliable signal | NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis) | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7) | |
| Ranibizumab (Lucentis) | Approved(overall) | Antibody fragment | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Eqrn (Cimerli) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Nuna (Byooviz) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016) | |
| Sotorasib | Approved | Small molecule | KRAS G12C | not yet graded | No reviewed efficacy summary in this indication | |
| Tucatinib | Approved | Small molecule | HER2 | Partial signal | NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Anbenitamab Repodatecan | Phase 3 | Antibody–drug conjugate | HER2 (biparatopic — extracellular domains II and IV) | not yet graded | No reviewed efficacy summary in this indication | |
| BAT5906 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Becotatug | Phase 3 | Monoclonal antibody | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| Botensilimab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| CKD-701 (Lucenbies) | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| HLX04 (Hanbeitai) | Phase 3 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| HLX04-O | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| IBI363 | Phase 3 | Multispecific antibody | PD-1 x IL-2Rα (IL2RA) | not yet graded | No reviewed efficacy summary in this indication | |
| INCA33890 | Phase 3 | Multispecific antibody | TGF-βR2 and PD-1 (conditional bispecific) | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ximluci) | Phase 3(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| S-1 | Phase 3 | Small molecule | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil) | not yet graded | No reviewed efficacy summary in this indication | |
| Surabgene Lomparvovec | Phase 3(overall) | Gene therapy / editing | VEGF-A | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Tarcocimab Tedromer | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Telisotuzumab Adizutecan | Phase 3 | Antibody–drug conjugate | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| MW02 | Phase 2/3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| N-Dihydrogalactochitosan | Phase 2/3 | Polysaccharide | STING and inflammasome pathways | not yet graded | No reviewed efficacy summary in this indication | |
| DSP107 | Phase 2 | Protein / enzyme therapeutic | SIRP-alpha/4-1BBL fusion protein | not yet graded | No reviewed efficacy summary in this indication | |
| Sirexatamab | Phase 2 | Monoclonal antibody | DKK1 (Dickkopf-1) | not yet graded | No reviewed efficacy summary in this indication | |
| A2B530 | Phase 1/2 | Cell therapy | CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker) | not yet graded | No reviewed efficacy summary in this indication | |
| NC410 | Phase 1/2(overall) | Protein / enzyme therapeutic | Collagen (LAIR-1 ligands) | not yet graded | No reviewed efficacy summary in this indication | |
| BBO-10203 | Phase 1 | Small molecule | RAS:PI3Kα protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| KRAS-Specific Autologous TCR-T Cell | Phase 1(overall) | Cell therapy | KRAS G12V presented on HLA-A*11:01 | not yet graded | No reviewed efficacy summary in this indication | |
| LY01008 | Phase 1 | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| LY4066434 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Palupiprant | Phase 1 | Small molecule | EP4 | Weak signal | No reviewed efficacy summary in this indication | |
| PF-07934040 | Phase 1(overall) | Small molecule | Pan-KRAS | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rimmyrah) | Phase 1(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Tusamitamab Sonditecan | Phase 1 | Antibody–drug conjugate | CEACAM5 | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Afiveg) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Eyluxvi) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Mynzepli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Vgenfli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PI3Kalpha Precision Therapy | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ranivisio) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rexatilux) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Telbermin | Discontinued | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow IBI305 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.